Alpha Breaking
Alpha BreakingBack to Alpha Breaking
Alpha BreakingAlpha Breaking
Bullish Sentiment

IDE: Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment

|Tuesday, June 2, 2026 at 11:02 AM ET
$IDE$BTK$ANT
IDE: Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment

Share this article

Spread the word on social media

Latest Updates

Jun 2, 1:42 PM

Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment

Financing supports the approval of U.S. Investigational Device Exemption (IDE), coronary clinical advancement, and expansion into below-the-knee peripheral (BTK) applications. SANTA CLARA, Calif., June 2, 2026 /PRNewswire/ -- Advanced NanoTherapies, Inc. (ANT), a clinical-stage medtech...

Source: PR Newswire
Jun 2, 1:42 PM

Advanced NanoTherapies Secures Over $31M Series B to Deliver First-of-its-Kind Dual-Drug (Paclitaxel and Sirolimus) Nanoparticle-Coated Balloon Platform for Vascular Treatment

Financing supports the approval of U.S. Investigational Device Exemption (IDE), coronary clinical advancement, and expansion into below-the-knee peripheral (BTK) applications. SANTA CLARA, Calif., June 2, 2026 /PRNewswire/ -- Advanced NanoTherapies, Inc. (ANT), a clinical-stage medtech...

Source: PR Newswire

Sources

Trade this headline in Alpha Contests.

Free practice contests — earn Alpha Coins
Enter a Contest

Explore More

Stay Ahead of the Market

Get breaking news on trending finance topics delivered as they happen. We find the stories others miss.

More Breaking News

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.